<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A nondifferentiating mouse myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> cell line produces differentiation-inhibiting factors </plain></SENT>
<SENT sid="1" pm="."><plain>One of these factors was purified as a homologue of nm23 </plain></SENT>
<SENT sid="2" pm="."><plain>The nm23 gene was isolated as a <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>-suppressor gene that exhibits low expression in high-level <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic cancer</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>The nm23 gene was overexpressed in <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) cells and a higher level of nm23-H1 expression was correlated with a poor prognosis in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Multivariate analysis of putative prognostic factors revealed that elevated nm23-H1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels significantly contributed to the prognosis of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The overexpression of nm23-H1 was also observed in various <z:hpo ids='HP_0004377'>hematological neoplasms</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>To use nm23 overexpression to determine the prognosis for <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, we established an enzyme-linked immunosorbent assay (ELISA) technique to determine the serum level of nm23-H1 protein </plain></SENT>
<SENT sid="7" pm="."><plain>This assay is far simpler than that used to determine nm23 <z:chebi fb="2" ids="33699">mRNA</z:chebi> by reverse transcriptase-polymerase chain reaction (RT-PCR) </plain></SENT>
<SENT sid="8" pm="."><plain>Using this system, we measured nm23-H1 protein levels in many <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Serum nm23-HI levels were significantly higher in patients with <z:hpo ids='HP_0000001'>all</z:hpo> of the <z:hpo ids='HP_0004377'>hematological neoplasms</z:hpo> tested (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>, <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo>, (ALL) <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo>) than in <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="10" pm="."><plain>An elevated serum nm23-H1 protein concentration predicted a poor outcome for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Especially in diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>), seram nm23-H1 protein levels were an important prognostic factor in planning an appropriate treatment strategy for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>The serum nm23-H I protein levels probably depend on the total mass of malignant cells overexpressing nm23-H1 </plain></SENT>
</text></document>